Jinan Hi-Tech issued a stock price change announcement that the in vitro diagnosis industry in which the company's subsidiary intends to acquire Eckway Biology is quite different from the company's existing business. After the completion of this acquisition, there is a certain degree of uncertainty about whether the underlying assets can be effectively integrated and managed. The underlying equity is still in a fully pledged state, and there is a situation in which a large amount of accounts receivable has not been recovered and the transactions between the relevant subjects of Xilong Science have not been settled, which may affect the delivery of the underlying assets or lead to the risk of potential losses.